IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Perkins Capital Management Inc.

Perkins Capital Management Inc. trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.6% during the third quarter, HoldingsChannel reports. The fund owned 9,700 shares of the company’s stock after selling 800 shares during the period. IDEXX Laboratories comprises about 4.6% of Perkins Capital Management Inc.’s investment portfolio, making the stock its 4th largest position. Perkins Capital Management Inc.’s holdings in IDEXX Laboratories were worth $4,901,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in IDXX. Csenge Advisory Group grew its stake in shares of IDEXX Laboratories by 21.4% during the 1st quarter. Csenge Advisory Group now owns 943 shares of the company’s stock worth $509,000 after acquiring an additional 166 shares in the last quarter. Empirical Finance LLC increased its stake in IDEXX Laboratories by 3.4% in the 1st quarter. Empirical Finance LLC now owns 3,021 shares of the company’s stock valued at $1,631,000 after buying an additional 100 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in IDEXX Laboratories by 42.8% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 20,835 shares of the company’s stock worth $11,249,000 after buying an additional 6,249 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of IDEXX Laboratories by 28.0% during the 1st quarter. Empowered Funds LLC now owns 1,039 shares of the company’s stock worth $561,000 after buying an additional 227 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of IDEXX Laboratories by 11.4% in the 1st quarter. SG Americas Securities LLC now owns 21,420 shares of the company’s stock valued at $11,565,000 after acquiring an additional 2,196 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on IDXX. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Barclays decreased their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday. BTIG Research started coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target for the company. JPMorgan Chase & Co. dropped their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $552.38.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $423.42 on Thursday. The company has a market capitalization of $34.67 billion, a price-to-earnings ratio of 40.83, a PEG ratio of 3.61 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12 month low of $404.74 and a 12 month high of $583.39. The stock’s 50 day moving average is $474.87 and its 200-day moving average is $485.88.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.53 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.